Zur Rose Group: Board of Directors nominates Walter Oberhänsli as Chairman and appoints Walter Hess as new CEO
Zur Rose Group AG / Key word(s): Personnel
Management changes at the Zur Rose Group
Board of Directors nominates Walter Oberhänsli as Chairman and appoints Walter Hess as new CEO
The Board of Directors is appointing Walter Hess to succeed Walter Oberhänsli as CEO after the General Meeting. He will assume the position after the General Meeting. Walter Hess has spent a year as Head Germany and CEO of DocMorris. Before switching to Germany he spent six years as Head Switzerland, and prior to that two years as managing director of German subsidiary Zur Rose Pharma GmbH, Halle (Saale). He holds a degree in business studies and had worked for the Zur Rose Group in Germany as an external advisor since 2008. His successor will be announced at a later date.
Prof. Stefan Feuerstein said: "With the planned change in the Board of Directors we are laying the groundwork for the continued further success of the Zur Rose Group in a very dynamic growth environment. We place our confidence in the operational management team under the CEO Walter Hess, who will ensure continuity." Walter Oberhänsli added: "I am honoured that the Board of Directors have placed their trust in me and nominated me as Chairman. The Zur Rose Group is in an outstanding position. On this strong foundation we will continue to drive ahead the transformation of the company into a comprehensive healthcare provider and health tech group - the Board of Directors and Group Management as a team, along with all the employees. I am delighted at the appointment of my successor. In a short space of time, Walter Hess has made an enormous human and technical contribution towards focusing our business in Germany on the future. The Board has great respect for him as an experienced manager with a proven track record and is confident he will successfully lead Zur Rose along its challenging growth path."
Investors and analyst contact
Zur Rose Group
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.
End of ad hoc announcement
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1242281|
|End of Announcement||EQS Group News Service|